The Journal of Allergy and Clinical Immunology
Volume 124, Issue 3 , Pages 422-427, September 2009

Genetics and pharmacogenetics of the leukotriene pathway

  • Kelan G. Tantisira, MD, MPH

      Affiliations

    • Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass
    • Pulmonary Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass
    • Corresponding Author InformationReprint requests: Kelan Tantisira, MD, MPH, Channing Laboratory, Brigham and Women's Hospital, 181 Longwood Ave, Boston, MA 02115.
  • ,
  • Jeffrey M. Drazen, MD

      Affiliations

    • Pulmonary Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass

Received 21 April 2009; received in revised form 25 June 2009; accepted 26 June 2009. published online 10 August 2009.

Leukotrienes are now established contributors to the inflammatory process in asthma, and leukotriene modifiers are mainstays in the therapy of asthma. This review focuses on published association studies implicating the role of leukotriene pathway genes in asthma pathogenesis and treatment response, specifically focusing on those genetic variants associated with asthma affection status, the development of aspirin-exacerbated respiratory disease, and pharmacogenetic response. Although published studies have been limited by small sample sizes and a lack of independent replication, multiple loci within multiple leukotriene pathway genes have now been associated in more than 1 study related to asthma or asthma treatment response. Those specific variants include 2 variants in the 5-lipoxygenase gene (ALOX5) that are both associated with response to 5-lipoxygenase inhibition and to leukotriene receptor antagonists, variants in genes encoding the 2 established cysteinyl leukotriene receptor antagonists (CYSLTR1 and CYSLTR2) that are both associated with asthma susceptibility in at least 2 independent populations, and a leukotriene C4 synthase promoter polymorphism (LTC4s) that has been associated with asthma affection status and asthma-exacerbated respiratory disease. Despite these successes, genetic investigations into this pathway remain in their formative stages. Future studies aimed at providing a broader scope of investigation through increased sample sizes and through genome-wide approaches are needed.

Key words: Leukotrienes, single nucleotide polymorphism, asthma, 5-lipoxygenase, zileuton, montelukast, pharmacogenetics

Abbreviations used: AERD, Aspirin-exacerbated respiratory disease, ALOX5, 5-Lipoxygenase gene, ALOX5AP, 5-Lipoxygenase–activating protein gene, CYSLTR1, Cysteinyl leukotriene receptor 1 gene, CYSLTR2, Cysteinyl leukotriene receptor 2 gene, 5-LO, 5-Lipoxygenase, LTC4S, Leukotriene C4 synthase gene, LTA4H, Leukotriene A4 hydrolase gene, OR, Odds ratio, SLCO2B1, Solute carrier organic anion transporter family, member 2B1, gene, SNP, Single nucleotide polymorphism

 

 Supported by the National Institutes of Health (U01:HL65899, K23:HG3983, and R01:HL92197).

 Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

PII: S0091-6749(09)00989-0

doi:10.1016/j.jaci.2009.06.035

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 3 , Pages 422-427, September 2009